Small Molecule Active Pharmaceutical Ingredients
Small Molecule Active Pharmaceutical Ingredients
Small molecule active pharmaceutical ingredients (APIs) form the foundation of most modern medicines. These chemically synthesized compounds typically have low molecular weights (generally under 1,000 Daltons) and well-defined, uniform structures. In contrast to biologics, their structural precision enables predictable behavior and efficient manufacturing.
Small molecules are often faster and more cost-effective to develop with advantages in chemical stability, longer shelf life, and simpler storage and distribution. Many can be stored at ambient conditions without strict cold chain requirements, reducing infrastructure needs, transportation complexity, and overall supply chain costs.
Their production relies on established synthetic chemistry processes, scalable technologies, and robust control of reactions and intermediates. This combination of reliability, flexibility, and efficiency, along with robust storage and seamless global distribution, makes small molecules essential to modern medicine, ensuring consistent, widespread access to over-the-counter and life-saving therapies for patients worldwide.
Key Issues
Small molecule API manufacturing presents a range of technical and operational challenges centered on safety, containment, and process control. Facilities must manage compounds with varying potency levels, often requiring specialized containment solutions such as isolators, gloveboxes, and closed handling systems. Processes frequently involve flammable solvents, reactive chemistry, and combustible dust, necessitating robust hazard management, ventilation, and emissions control strategies.
In multi-product environments, controlling cross-contamination and ensuring effective cleaning between campaigns are critical to maintaining product integrity. Additionally, modern facilities rely on integrated digital systems for process monitoring, data management, and traceability, requiring strong data governance and system reliability. Addressing these factors through thoughtful design and operational strategies is essential for safe, efficient, and flexible API manufacturing.
How Fluor Helps
Fluor partners with pharmaceutical manufacturers to translate complex small molecule processes into safe, scalable, and efficient production facilities. Leveraging deep EPCM expertise, Fluor integrates synthesis, isolation, and purification with robust containment, solvent handling, hazard mitigation, and emissions management. We design flexible, multi-product facilities and optimize layouts, material flow, and digital systems to enable reliable, high-quality API production and efficient scale-up from development through commercial manufacturing.
Process Features
Small molecule API production spans from early development to large-scale commercial manufacturing. Processes are typically based on organic synthesis, followed by isolation and finishing steps such as crystallization or precipitation, phase separation (filtration, centrifugation or agitated Nutsche filter dryers), drying, and milling. While batch processing remains common, continuous manufacturing is increasingly adopted to improve efficiency and consistency.
Operations often involve solvent-based chemistries under a wide range of temperatures, pressures, and material conditions, requiring careful selection of equipment such as glass-lined vessels or corrosion-resistant alloys. Process performance depends on consistent control of reaction conditions, raw material quality, and impurity profiles, supported by robust analytical methods ensuring specificity across closely related impurities. This ensures reliable, scalable production while maintaining product quality from development through commercial manufacturing, with early identification of impurity pathways and effective purge strategies strengthening overall process control.
Facility Features
Small molecule API facilities are typically designed with multi-story layouts to support efficient material handling and gravity-based transfers. Operations are largely contained within closed systems, with controlled charging and discharging areas to maintain safety and product integrity. Facility layouts are driven by potency and process requirements, incorporating appropriate segregation of spaces, personnel, and material flows and pressure differentials. Given the frequent use of flammable solvents and reactive materials, especially in drying, milling and solvent handling operations, facilities integrate robust hazard mitigation measures, including classified electrical systems, ventilation, gas detection, and solvent or dust explosion protection construction, equipment and strategies (ex. vent, suppress, isolate). Equipment selection, room configuration, and structural design are carefully aligned to process conditions, ensuring safe, flexible, and efficient operations across a range of manufacturing scales.
Fluor Projects
Advanced Pharmaceutical Ingredient
Location: Midwest USA
Scope: EPCM
Fluor delivered the largest pharmaceutical project to date that included large-scale peptide manufacturing facilities, providing EPCM service from conceptual design through construction management for the initial site and later expansions. Work included 600-acre greenfield campus development for various drug classes with the incorporation of integrated utilities, solvent logistics, and supporting infrastructure, enabling high-containment, scalable production. Small molecule buildings feature glass-lined carbon steel and Hastelloy reaction vessels, crystallization, and agitated filter drying for synthesis; and high-performance liquid chromatography, film evaporation and distillation, tangential flow filtration, crystallization, and drying for purification.
CDMO Study
Location: North Carolina, USA
Scope: Feasibility and Conceptual Design
Fluor performed conceptual design for a 535,000-square-foot greenfield, multi-technology CDMO facility, enabling integrated development through commercial manufacturing. The campus includes capabilities for traditional small molecules, highly potent small molecule compounds (39,000-square-foot), recombinant protein and monoclonal antibody biologics, and antibody-drug conjugates, with dedicated drug substance production, fill-finish, and extensive process and analytical laboratories (159,000-square-foot). Fluor’s work established early cost, schedule, and design frameworks enabling flexible, scalable, and efficient end-to-end pharmaceutical production supporting diverse modalities.
Active Pharmaceutical Ingredient Manufacturing Facility
Location: Colorado, USA
Scope: Engineering and Construction Management
Fluor provided basic and detailed design and procurement services for the new facility that will manufacture advanced intermediates and chemically synthesized active pharmaceutical ingredients (APIs).
Business Inquiries
Contact Fluor's sales team to learn how Fluor can help you with your business needs and what solutions Fluor offers in your industry. See the buttons below for questions on other topics.